To hear about similar clinical trials, please enter your email below

Trial Title: Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides

NCT ID: NCT05526638

Condition: Mycosis Fungoides

Conditions: Official terms:
Mycoses
Mycosis Fungoides

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: prospective cohort study

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Radiation
Intervention name: ultraviolet phototherapy
Description: thrice weekly sessions of ultraviolet phototherapy
Arm group label: New/ recurrent mycosis fungoides patients

Summary: Estimation of serum and tissue level of IL-15 and IL-15 R α in mycosis fungoides prior to after treatment.

Detailed description: Twenty patients will be recruited from the cutaneous lymphoma clinic who are either recently diagnosed with MF or presenting with recurrent MF following cessation of treatment. An informed written consent will be obtained from all patients. Clinical assessment: Patients will be assessed clinically for extent by BSA as well as MF staging and type. For MF staging, in addition to extent, diagnostic skin biopsies will be assessed for depth of the infiltrate. Radiological assessment including chest x-ray, pelvi-abdominal ultrasound as well as lymph node examination, ultrasound and biopsy if required. Biochemical assessment including complete blood count, liver and kidney function tests, lipid profile as well as lactate dehydrogenase and beta 2 microglobulin. Standardized photographs will be taken at initial assessment as well as following resolution of the biopsied lesion. Baseline biochemical assessment at the beginning of the study: Serum samples as well as 4mm lesional punch skin biopsies will be taken prior to starting phototherapy treatment to assess serum and tissue level of IL-15 and IL-15 R α level using enzyme-linked immunosorbent assay (ELISA). Phototherapy treatment: Patients with superficial lymphocytic infiltrate will be assigned to either NB-UVB sessions, while those with deep infiltrate will be assigned to PUVA. Patients will undergo thrice weekly sessions. Patients will be clinically assessed on monthly basis to monitor response to treatment and record any side effects. Biochemical reassessment: Serum and lesional biopsies will be retaken following resolution of the biopsied lesion to assess serum and tissue level of IL-15 and IL-15 R α level using enzyme-linked immunosorbent assay (ELISA). Afterwards, the biopsied lesion will be covered if the patients was having other unresolved lesions and monthly follow up will be carried to detect lesional recurrence. Any reported recurrence during the estimated study duration of 6 months will be re assessed for both serum and tissue level of IL-15 and IL-15 R α level using enzyme-linked immunosorbent assay (ELISA). Twenty healthy controls will be recruited and assessed for both serum and tissue level of IL-15 and IL-15 R α level using enzyme-linked immunosorbent assay (ELISA).

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Subjects with mycosis fungoides; newly diagnosed or recurrent after cessation of treatment Exclusion Criteria: - Patients with any contraindication to phototherapy (e.g., any other skin cancers or photosensitivity); or to psoralen (e.g., liver disease). - Subjects with history of solid or hematological malignancy as leukemia. - Patients with autoimmune disease as SLE. - Patients who received treatment for the past one month. - Pregnant and lactating females.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: Cutaneous Lymphoma clinic, Cairo university hospitals

Address:
City: Cairo
Country: Egypt

Status: Recruiting

Contact:
Last name: Nourhan Emad, MSc

Phone: 01100709360
Email: nourhanemad693@gmail.com

Contact backup:
Last name: Rania Mogawer, MD

Phone: 01068165330
Email: raniamogawer@kasralainy.edu.eg

Start date: January 1, 2023

Completion date: May 30, 2023

Lead sponsor:
Agency: Cairo University
Agency class: Other

Source: Cairo University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05526638

Login to your account

Did you forget your password?